Asset 1

TruSight™ Oncology 500 (TSO500)

Streamlined Parallel Histopathology and NGS Workflows to Detect Clinically Relevant DNA and RNA Variants in Various Solid Tumor Indications

Discovery Genomics' TSO500 Solid Tumor NGS service provides high sensitivity detection of genomic variants across 523 DNA genes and 55 RNA fusion events in most major cancer indications and sample types, including microsatellite instability (MSI) and tumor mutational burden (TMB).


Our TSO500 NGS services provide pan-cancer genomic biomarker analysis of SNVs, InDels, CNVs, Fusions, TMB, and MSI to enable:

Service Performance Data

Using commercially available reference standards in our optimized and automated nucleic acid extraction, library construction, and sequencing workflows, we demonstrate the accuracy, sensitivity, and reproducibility of our TSO500 ctDNA NGS service




> 2% Allele Fractions



TSO500 Solid Tumor NGS Services Deliverables

Horizon FFPE gDNA Reference Control from Run 1

Sample Report

SeraCare NTRK Fusion Reference Control from Run 1

Sample Report

Colon Carcinoma Sample Report

Sample Report

TSO500HT v2.2 Output files

DNA Results

RNA Results

Combined DNA + RNA Results

QC and Metrics Files

Sample Input Requirements

Optimized Methods for Sequencing RNA from FFPE Samples

Download this white paper to learn more about our optimized protocol that retains and extracts longer RNA molecules without impacting DNA quality or yield.

Download Whitepaper

Related Products & Services

FFPE and Other Oncology Specimens

Optimized Dual DNA/RNA Extraction Services

Molecular Pathology Services

TSO500 Liquid Biopsy
NGS Services

Other Sequencing

Contact Us Today

Quick Links


Development and Clinical
Trial Solutions